YOLFTbeta
Eurobio Scientific SA

Eurobio Scientific SA

ALERS · PA · Healthcare / Medical Devices

26.40EUR+0.05 (+0.19%)

Price History

Full chart

Market Stats

Previous Close26.35
Open26.40
Day Range26.40 – 26.50
52-Week Range19.20 – 25.50
Volume529
Market Cap248.18M
P/E (TTM)35.86
Forward P/E8.82
EPS0.70
Dividend Yield0.00%
Beta0.70
50-Day Avg21.48
200-Day Avg22.46

About

Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts; AlloMap, for heart transplant follow up; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies; TQS (Tetanus Quick Stick), a rapid test used in emergency departments or pharmacies to assess the vaccination status or immune protection of patients against tetanus; EBX molecular biology ranges in the field of infectious diseases; and EndoPredict range, a second-generation multigene expression test for postmenopausal women with early-stage breast cancer, ER positive, and HER2 negative, as well as Prolaris. It also provides GenDx, EurobioPlex, FungiLine, Biosafety PKA, and immunology products. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Denis Fortier
  • Employees443
  • Headquarters7 avenue de Scandinavie, Les Ulis, France, 91953, France
  • Websitehttps://www.eurobio-scientific.com

Leadership

  • Mr. Denis FortierCEO & Chairman · b. 1968
  • Mr. Olivier BoscDeputy CEO & CFO · b. 1974
  • Ms. Cathie MarsaisDeputy CEO, COO, Operations, Affairs Quality & Regulatory · b. 1982
  • Mr. Jean-Michel Carle GrandmouginDeputy GM, Business Developer & Director · b. 1961
  • Mr. Maarten Penning Ph.D.CTO and Director of R&D
  • Ms. Hanneke Merkens Ph.D.CMO, COM and Manager of International Product, Infectious & Transplant
  • Mr. Thomas MoreauxCHRO & Ressources Humaines
  • Mr. Thomas IffChief Business Officer

Financials

Income Statement

Currency: EUR2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.38M4.22M4.89M8.42M4.99M5.39M31.22M31.04M29.78M27.82M42.78M51.07M59.48M188.86M184.71M152.61M130.65M154.95M169.00M
Growth (%)--21.65%+15.95%+72.08%-40.70%+7.91%+479.47%-0.55%-4.07%-6.56%+53.75%+19.38%+16.46%+217.54%-2.19%-17.38%-14.39%+18.60%+9.07%
Cost of Revenue8.61M9.88M8.98M--449.00K23.56M23.06M25.09M23.01M29.82M33.48M41.13M83.25M87.27M87.56M73.16M82.99M100.60M
Gross Profit-3.22M-5.66M-4.09M8.17M4.99M4.94M7.65M7.98M4.69M4.81M12.96M17.59M18.35M105.61M97.44M65.04M57.49M71.95M68.40M
Gross Margin-59.87%-134.13%-83.65%97.07%100.00%91.67%24.52%25.72%15.75%17.29%30.29%34.44%30.85%55.92%52.75%42.62%44.00%46.44%40.47%
Operating Expense4.57M5.74M5.57M15.14M13.09M11.41M14.68M13.67M13.03M12.20M18.74M18.75M17.78M24.40M25.46M34.17M47.35M58.55M52.95M
Operating Income-7.79M-11.39M-9.66M-6.97M-8.10M-6.47M-7.02M-5.69M-8.34M-7.39M-5.79M-1.16M569.00K81.21M71.99M30.87M10.14M13.40M15.45M
Operating Margin-144.74%-270.06%-197.44%-82.85%-162.16%-120.18%-22.50%-18.32%-28.01%-26.56%-13.52%-2.27%0.96%43.00%38.97%20.23%7.76%8.65%9.14%
EBITDA-7.26M-10.93M-8.90M-6.27M-6.07M-6.38M-4.66M-3.36M-4.30M-4.95M-2.58M4.35M6.94M88.57M79.63M40.49M24.55M20.40M32.04M
EBITDA Margin-134.78%-259.16%-181.95%-74.45%-121.63%-118.45%-14.92%-10.83%-14.43%-17.80%-6.03%8.51%11.67%46.90%43.11%26.53%18.79%13.17%18.96%
Net Income-7.34M-8.93M-7.70M-7.75M-7.10M-5.77M-5.99M-5.49M-5.88M-7.73M-9.97M-2.77M3.15M73.48M60.54M24.94M4.83M4.00M4.87M
Net Income Margin-136.30%-211.54%-157.42%-92.04%-142.21%-107.11%-19.20%-17.67%-19.74%-27.79%-23.30%-5.42%5.30%38.91%32.78%16.34%3.70%2.58%2.88%
R&D--8.98M8.48M7.72M6.98M7.35M5.64M3.96M3.16M2.11M1.42M1.64M1.90M3.44M3.47M8.56M4.64M4.60M
R&D as % of Total Revenue--183.65%100.74%154.59%129.63%23.53%18.17%13.31%11.36%4.93%2.78%2.75%1.00%1.86%2.27%6.56%3.00%2.72%
Interest Expense479.00K363.00K413.00K1.96M1.36M48.00K74.00K270.00K388.00K268.00K675.00K1.01M748.00K619.00K455.00K1.29M4.42M5.60M2.00M
Interest Expense % of Total Revenue8.90%8.60%8.44%23.27%27.34%0.89%0.24%0.87%1.30%0.96%1.58%1.99%1.26%0.33%0.25%0.84%3.39%3.61%1.18%

Balance Sheet

Currency: EUR2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets37.59M29.85M36.55M31.26M17.60M38.49M33.41M40.50M35.71M31.89M71.57M69.90M81.01M172.30M209.22M330.42M316.33M257.17M256.76M
Total Liabilities19.52M20.11M11.09M12.07M4.04M13.99M12.85M12.55M12.40M19.66M39.88M40.27M44.44M64.45M49.00M157.75M141.16M78.31M72.83M
Total Equity18.07M9.74M25.46M19.19M13.57M24.50M20.56M27.94M23.30M12.22M31.69M29.62M36.56M107.11M159.91M172.34M175.17M178.85M183.92M
Cash6.40M5.65M2.10M5.16M7.59M6.66M3.15M2.98M4.59M7.12M10.44M9.89M7.02M65.10M92.92M47.49M49.30M21.77M20.32M
Total Debt14.82M14.78M317.00K6.71M15.00K2.81M2.17M8.86M6.82M6.53M20.86M23.72M19.91M30.36M16.34M114.27M100.66M34.05M16.02M
Net Debt8.41M9.13M-1.79M1.55M-7.58M-3.85M-976.00K5.88M2.24M-584.00K10.42M13.83M12.23M-35.40M-77.24M66.11M52.03M12.28M-4.30M

Cash Flow

Currency: EUR2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.93M-9.62M-6.71M-5.80M-6.02M-4.45M-4.90M-3.38M-2.44M-3.32M2.48M-523.00K4.99M54.93M65.92M43.07M26.77M16.70M18.85M
Investing Cash Flow-877.00K-1.18M-343.00K-135.00K-72.00K-5.75M-213.00K-255.00K-47.00K-997.00K-11.36M-1.55M-4.39M-3.98M-5.47M-141.76M-318.00K-10.74M-12.89M
Financing Cash Flow13.32M219.00K16.33M1.11M-6.67M7.12M1.13M11.77M27.00K547.00K12.78M1.27M-4.01M7.67M-23.75M82.31M-23.50M-72.09M-8.16M
Capital Expenditure1.05M1.18M343.00K220.00K149.00K87.00K574.00K658.00K155.00K200.00K3.91M1.63M1.59M2.30M1.85M2.83M4.05M3.26M12.57M
Free Cash Flow-5.99M-10.79M-7.05M-6.02M-6.17M-4.53M-5.47M-4.04M-2.60M-3.52M-1.44M-2.15M3.40M52.02M63.61M39.01M22.71M13.45M6.28M
Dividends Paid-------3.00K4.00K----------
FCF to OCF121.30%112.24%105.11%103.79%102.47%101.96%111.71%119.44%106.34%106.03%-58.06%411.28%68.10%94.69%96.51%90.58%84.85%80.51%33.33%
Dividend Paid to FCF--------0.07%-0.15%----------

Earnings

Report DateMar 26, 2014Sep 15, 2014May 6, 2016Nov 2, 2016Apr 27, 2017Nov 22, 2017May 9, 2018Oct 9, 2018Apr 17, 2019Nov 25, 2019Apr 14, 2020Oct 16, 2020Apr 30, 2021Oct 13, 2021Apr 7, 2022Oct 11, 2022Apr 5, 2023Sep 24, 2024Apr 28, 2025Sep 24, 2025Oct 13, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.00-0.00--0.000.000.000.00
EPS Actual0.000.00-1.00-1.02-0.96-0.67-0.49-0.09-0.190.030.002.264.252.892.641.860.580.400.000.230.23
Surprise---------------------
Timing--------------Pre-marketPre-marketAfter-hours----

Key Statistics & Ratios

Market Cap248.18M
Enterprise Value249.07M
Trailing P/E35.86
Forward P/E8.82
Price / Sales1.44
Price / Book1.38
EPS0.70
Book Value19.01
Revenue (TTM)172.26M
Gross Profit (TTM)79.06M
EBITDA22.78M
Profit Margin4.18%
Operating Margin10.02%
Return on Equity3.86%
Return on Assets2.42%
Shares Outstanding9.89M
Shares Float843.62K
Beta0.70
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 1, 20171:20
  • Jan 30, 2017666:623